Plain-English translation of NCT03198546 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing GPC3-CAR-T cell therapy, a personalized cancer treatment for advanced liver cancer. Doctors will take immune cells (T cells) from your blood, genetically modify them in a laboratory to recognize and attack your cancer cells, and then return the modified cells to your body where they can work to fight the disease.
Standard treatments for advanced liver cancer don't work well for all patients. This trial explores whether training your own immune cells to specifically target cancer cells could offer a new treatment option for people whose cancer hasn't responded to other therapies.
You likely qualify if…
You likely don't qualify if…
First, doctors will take a small tissue sample from your tumor to confirm it has the target protein, then collect blood to extract your immune cells. The cells are sent to a lab where they are genetically modified and grown in larger numbers over several weeks. Once ready, the trained cells are given back to you through an infusion into your bloodstream or directly into the tumor area. You'll have close follow-up visits to monitor how you respond and watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China